Press Releases

 
Press Releases
Date Title and Summary View
May 10, 2016 BOSTON, May 10, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its first quarter 2016 financial results, and provided an update on the Company's clinical program for belor...
May 3, 2016 BOSTON, May 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will host a conference call on Tuesday, May 10, 2016 at 4:30 p.m. ET to discuss i...
Apr 3, 2016 --bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improvement in hyperphagia-related behaviors in PWS patients-- --Beloranib was associated with improvement in total cholesterol, LDL cholesterol and other markers of cardiometabolic risk -- ...
Mar 28, 2016 BOSTON, March 28, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that new scientific data from the bestPWS ZAF-311 study, a pivotal, double-blind, pla...
Mar 9, 2016 BOSTON, March 09, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its fourth quarter and full year 2015 financial results, and provided an update on the Co...
Mar 8, 2016 BOSTON, March 08, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that Thomas O. Daniel, M.D. has been appointed to the Company's Board of Directors, eff...
Mar 2, 2016 BOSTON, March 02, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will host a conference call on Wednesday, March 9, 2016 at 4:30 p.m. ET to...
Mar 1, 2016 BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that Thomas Hughes, Chief Executive Officer of Zafgen, will present at the upcoming Cowen...
Feb 29, 2016 BOSTON, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its ongoing support of patients with rare diseases — including the Prader-Willi syndrome (PWS)...
Feb 18, 2016 - Beloranib demonstrates statistically and clinically significant improvements in body weight and glycemic control over six months of randomized treatment —-Conference call scheduled for 8:30 AM Eastern Time-BOSTON, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Zafge...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase